Mayo Clinic College of Medicine and Science

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

Retrieved on: 
Thursday, October 5, 2023
Annual general meeting, Senior, Mayo Clinic College of Medicine and Science, Doctor of Philosophy, Advocacy, Trial of the century, Pediatrics, MD, Medical Affairs Bureau, NPC, Zebra, Safety, Disease, Niemann–Pick disease, Therapy, Medical genetics, Child, CNS, Pharmaceutical industry, Neurology, Science

CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52nd Child Neurology Society (CNS) Annual Meeting. This meeting will be held October 4-7, 2023, in Vancouver, Canada. The presentations will focus on arimoclomol, Zevra’s late-stage pipeline program in development for the treatment of Niemann-Pick Disease type C (NPC), including 48 months of efficacy and safety data captured through the double-blind and open-label extension phases of the registrational trial, as well as methodology related to establishing an early access program with real-world data collection capabilities.

Key Points: 
  • CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52nd Child Neurology Society (CNS) Annual Meeting.
  • This meeting will be held October 4-7, 2023, in Vancouver, Canada.
  • “Our team is eager to highlight our arimoclomol program at the 52nd CNS Annual Meeting and engage with the key child neurologists who are treating devastating conditions like NPC where few therapeutic options exist,” said Daniel Gallo, PhD, Senior Vice President of Medical Affairs and Advocacy for Zevra.
  • “The arimoclomol data demonstrate the importance of understanding the long-term efficacy and treatment approach for this potential new therapy for NPC.”
    Marc Patterson, MD, Professor of Neurology, Pediatrics, and Medical Genetics, Mayo Clinic College of Medicine and Science, Rochester, MN

Dr. David Gullen to Hand Over Flinn Foundation Board Chair After More Than Two Decades of Service

Retrieved on: 
Thursday, March 30, 2023
Philanthropy, Health, Foundation, General Health, Research, Science, Civic, Reimann, University of Oxford, Duke University, Mayo Clinic, Translational Genomics Research Institute, Arizona Center, University, Internal medicine, Culture, Physician, American Board of Internal Medicine, Mayo Clinic College of Medicine and Science, PET, Multimedia, Arizona Public Service, Private practice, Medicine, Princeton University, American College of Physicians, American Board of Commissioners for Foreign Missions, Neuroscience, Entrepreneurship, Arizona State University, Medical Center, Washington University School of Medicine, Strong Memorial Hospital, Associate, Growth, Hospital, Regent, WebPT, American College, ST, Havasupai Tribe v. the Arizona Board of Regents, Psychiatry, Roadmap, Microbiology, Pension fund, Pharmaceutical industry, Management, Nursing, Phoenix

Dr. David Gullen, the longest-serving member of the Flinn Foundation board of directors, is stepping down as chair after 21 years of leading the philanthropic grantmaking organization.

Key Points: 
  • Dr. David Gullen, the longest-serving member of the Flinn Foundation board of directors, is stepping down as chair after 21 years of leading the philanthropic grantmaking organization.
  • View the full release here: https://www.businesswire.com/news/home/20230329006005/en/
    Dr. David Gullen served as chair of the Flinn Foundation board of directors from 2002 to March 2023.
  • Gullen, a physician who practiced internal medicine in the Phoenix area for nearly 35 years before retiring, joined the Flinn board in 1989 and was named chair in 2002.
  • The Flinn Scholars Program was a new initiative when Gullen first joined the board and continues today as the most prestigious college scholarship in Arizona.

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Communications, Health, Clinical Trials, Publishing, Biotechnology, Woman, Associate, Arm, Leukopenia, Anemia, Fulvestrant, Progression-free survival, Mayo Clinic College of Medicine and Science, MD, PFS, Patient, Adenosine, Mitosis, CDK, Everolimus, Neutropenia, Phase, Fatigue, JAMA Oncology, Lymphocytopenia, Aurora kinase A, Apoptosis, Pharmaceutical industry

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer have been published online in JAMA Oncology.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer have been published online in JAMA Oncology.
  • The Phase II randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium.
  • The trial enrolled postmenopausal women with endocrine-resistant, HER2–negative metastatic breast cancer who were previously treated with fulvestrant.
  • “We greatly look forward to advancing alisertib into additional clinical trials for ER-positive HER2-negative breast cancer.”

The Galien Foundation Appoints Michael Rosenblatt, M.D., as Chairman of Prix Galien USA Awards Committee

Retrieved on: 
Thursday, January 5, 2023
Knowledge, Linda, University of Washington, Columbia University Irving Medical Center, Human Genome Sciences, Bill & Melinda Gates Foundation, Merck & Co., Medtech, Medical genetics, Research, Koch Institute, Merck, Bill, Physiology, Mayo Clinic College of Medicine and Science, Fred Hutchinson Cancer Research Center, Patient, MIT Jameel Clinic, Committee, Pleasure, Affiliation, Mayo, Mayo Clinic, Health, American Cancer Society, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Flagship Pioneering, Pharmaceutical industry, Management, Nobel, Biophysics, Medicine, Biology

"Following the illustrious leadership of both P. Roy Vagelos and then Susan Desmond-Hellmann in this role, I am deeply honored to serve as the next Chairman of the Prix Galien USA Committee.

Key Points: 
  • "Following the illustrious leadership of both P. Roy Vagelos and then Susan Desmond-Hellmann in this role, I am deeply honored to serve as the next Chairman of the Prix Galien USA Committee.
  • The Prix Galien recognizes the teams in the biopharmaceutical industry that have created the most important innovations that improve health and address unmet medical needs.
  • I am most enthusiastic about taking on new responsibilities to advance the mission of The Galien Foundation.
  • I look forward to October 26, 2023, when we announce the next group of Prix Galien USA awardees and celebrate their achievements."

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention

Retrieved on: 
Friday, December 2, 2022
Doctor of Pharmacy, Pharmacy technician, Research, Degenerative disease, Pharmacist, Patient, Society, Environment, DPLA, Associate, BS, B Lab, Yale New Haven Hospital, Health, Benefit corporation, Partnership, ASHP, Boston Medical Center, Neonatology, MHA, CPE, Community, MBA, Medicine, Faculty, BCPS, Hospital, Assistant, Checklist, Assembly, Mayo Clinic College of Medicine and Science, American Society of Health-System Pharmacists, Mayo Clinic, CARY, Cystic fibrosis, Education, B Corporation (certification), Pharmaceutical industry, Management, Fine chemical, Chiesi Farmaceutici, Pharmacy

As a Certified B Corporation, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals.

Key Points: 
  • As a Certified B Corporation, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals.
  • CARY, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced its sponsorship of the ASHP (American Society of Health-System Pharmacists) Advantage initiative to support pharmacy technician recruitment and retention.
  • The ASHP Advantage initiative is designed to address the pharmacy technician shortage through educational strategies, tools and resources to improve recruitment and retention efforts.
  • Launch of the Pharmacy Technician Recruitment and Retention Resource Center, which will include detailed information about the initiative, a checklist of recruitment and retention strategies to assist pharmacists in their efforts, examples of career ladders for pharmacy technicians, and other resources.

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Nausea, Accounting, GLOBE, Triangle Park (Quezon City), Clinical trial, Security (finance), Pain, Marketing, Patient, ASCEND, Dartmouth, Food, Terminology, Migraine, DHE, International Headache Society, Risk, NDA, MBS, Industry, Mayo Clinic College of Medicine and Science, University of Zambia School of Medicine, SAN, Safety, Nasdaq, Magic: The Gathering core sets, 1993–2007, CMC, Geisel School of Medicine, Guideline, COVID-19, Chemistry, Neurology, File, FDA, DC, MedStar Georgetown University Hospital, DRS, Achievement, Plasma, Company, IHS, Research, Dihydroergotamine, Freedom, Pharmaceutical industry, Dietary supplement, Medical device, Science, Cephalalgia

(Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2022 and summarized progress in its STS101 development program.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2022 and summarized progress in its STS101 development program.
  • Satsuma is on track to report topline results from the SUMMIT trial in the fourth quarter of 2022.
  • In May 2022, Satsuma completed clinical and chemistry, manufacturing and controls (CMC) pre-NDA meetings with the FDA for STS101.
  • Research and development expenses were $12.5 million for the second quarter 2022, compared to $8.4 million for the same period of 2021.

FDA Clears Thermo Scientific EliA RNA Pol III and EliA Rib-P Tests for Use in U.S.

Retrieved on: 
Thursday, June 9, 2022
FDA, Medical Devices, Other Health, Health, Genetics, Science, Applied Biosystems, Meta-analysis, Lupus, Arthritis, Research, Patheon, Autoantibody, Mayo Clinic College of Medicine and Science, SLE, Systemic scleroderma, Invitrogen, American College, Autoimmunity Reviews, Immunoglobulin G, PPD, Connective tissue, Scleroderma, FDA, Patient, Medical laboratory, RNA polymerase III, Fisher Scientific, BMC Medicine, Laboratory, Health, Review, Antibody, Diagnosis, Thermo Fisher Scientific, Autoimmunity, CTD, Efficiency, Systemic, Pharmaceutical Services Negotiating Committee, Elia, RNA polymerase, Mindful Scientific Inc., Medical device, Vaccine, Dermatology

Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
  • [2] The EliA RNA Pol III test completes a criteria based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
    A subset of SLE patients present with monospecific Ribosomal P antibodies.
  • The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases.
  • For more information on the Thermo Scientific EliA RNA Pol III and EliA Rib-P tests, please visit https://www.thermofisher.com/phadia .

Dr. Jack Jeng Joins Hone Health as Chief Medical Officer

Retrieved on: 
Thursday, May 26, 2022
Online Retail, Retail, Health, Consumer, General Health, Men, Medical Affairs Bureau, Physician, BD (company), Mayo Clinic College of Medicine and Science, Ageing, Metabolism, Multimedia, Environment, Health, Testosterone, Quality of life, Hormone replacement therapy, University of California, San Francisco, Depression, Electrical engineering, Research, DO, UCSF, HRT, Man, University, Irritability, Reproduction, FACS, Hormone, Medical Center, Acquisition, Growth, Arizona State University, Fatigue, CEO, Medicine, Birth control, Health insurance, Hone, MD, Online Retail, Retail, Health, Consumer, General Health, Men

Hone Health, the premier mens online clinic that helps men optimize their health by addressing hormonal imbalances and low testosterone, announced today the addition of Dr. Jack Jeng as their chief medical officer.

Key Points: 
  • Hone Health, the premier mens online clinic that helps men optimize their health by addressing hormonal imbalances and low testosterone, announced today the addition of Dr. Jack Jeng as their chief medical officer.
  • through the acquisition of Scanwell Health, where he was Chief Medical Officer.
  • We are so pleased to welcome Dr. Jack Jeng to the Hone team, stated Saad Alam, co-founder and CEO of Hone Health.
  • Im thrilled to be a part of the mens health movement to eliminate any barriers or stigma associated with seeking care in a proactive and personalized way, said Jack Jeng, M.D., Chief Medical Officer at Hone Health.